Skip to content

Efficacy and Safety of Lactobacillus acidophilus YT1 Probiotics on menopausal symptoms; A 12week, Multi-center, Randomized, Double-blind, Placebo-Controlled Clinical Trial

Efficacy and Safety of Lactobacillus acidophilus YT1 Probiotics on menopausal symptoms; A 12week, Multi-center, Randomized, Double-blind, Placebo-Controlled Clinical Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0003211
Enrollment
80
Registered
2018-09-21
Start date
2017-06-12
Completion date
Unknown
Last updated
2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : Lactobacillus acidophilus YT1 2 g / cell and placebo were randomly assigned to receive one dose (once per day) for 12 weeks (one dose) (without water) or with water

Sponsors

Korea Food Research Institute
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1)40 to 60 year-old women with FSH 30 mIU / ml or more who have passed one year since the last menstrual period or who have no uterus 2) Women with a kupperman index score of 20 or higher 3) Women who have agreed to participate in this human body test before the start of the human body test and who have written an informed consent

Exclusion criteria

Exclusion criteria: 1) Women with a body mass index (BMI) greater than 30 kg / m2 2) Women using hormone preparations such as female hormones or similar hormone preparations (plant extracts, etc.) within 3 months 3) Women with a history of endometrial hyperplasia, uterine cancer, endometrial cancer, breast cancer or breast disease, sex hormone related cancer 4) A woman with a history of severe migraine within the past year or who has been diagnosed with thromboembolism, cerebrovascular disease, myocardial infarction, unstable angina, or underwent coronary angioplasty 5) Women with severe mental illnesses such as depression and anxiety disorder, or those currently taking psychotropic drugs such as antidepressants 6) Women with irregular uterine bleeding after 1 year of menopause 7) Patients with uncontrolled hypertension (160 /100mmHg or more, After 10 minutes of stabilization) 8) Uncontrolled diabetes mellitus patients (fasting blood sugar more than 180mg/dL or starting a new drug due to diabetes within 3 months) 9) Patients with thyroid disease whose TSH is less than or equal to 0.1 µU / ml or more than 10 µU / ml 10) drug or alcohol abuser 11) If ALT or AST exceeds 3 times the normal upper limit of the research institute 12) Creatinine exceeds twice the normal upper limit of research institute 13) Mammography / PAP smear When a clinically significant abnormality (BI-RADS Category 0 or 3 or more, PAP smear is absent up to ASCUS) is confirmed 14) Have participated or planned to participate in other clinical trials within the past month 15) If the tester judges that the test is inappropriate for this human body test 16) Women using thyroid hormone preparations, clonidine, anticoagulants or antithrombotic agents (Warfarin, Clipidogrel, etc.) within 3 months 17) Women who took medicines or health functional foods related to women's menopause within a month 18) Women who have taken probiotics within 2 weeks of screening 19) Those taking or administering a therapeutic agent for osteoporosis, such as a bisphosphonate preparation

Design outcomes

Primary

MeasureTime frame
KMI (kupperman index, 11 items) Total point change

Secondary

MeasureTime frame
Modified KMI's individual item scores (KMI 11 items, vaginal dry items);ALP (Alkalinephosphatase);Urine DPD (deoxypyridinoline);Assessment of quality of life;Adverse reaction;Clinical pathology examination;Vital signs (blood pressure, pulse);E2(Estradiol);Endometrial thickness;OC(Osteocalcin);weight;FSH(Follicle Stimulating Hormone)

Countries

Korea, Republic of

Contacts

Public ContactLee Young

Konkuk University Medical Center

chess1@unitel.co.kr+82-2-2030-7643

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026